<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500253</url>
  </required_header>
  <id_info>
    <org_study_id>RNN-56-07-KE</org_study_id>
    <nct_id>NCT00500253</nct_id>
  </id_info>
  <brief_title>Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma</brief_title>
  <official_title>Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the utility of exhaled nitric oxide measurement (FeNO) in&#xD;
      treatment monitoring in children with asthma.&#xD;
&#xD;
      According to the aim of the study following assumptions are formulated:&#xD;
&#xD;
        1. Comparison of annual cumulative steroid dose, number of bronchodilator doses taken,&#xD;
           number of asthma exacerbation, number of hospitalisation due to asthma, between group of&#xD;
           children with asthma with FeNO monitored treatment (study group), and group of children&#xD;
           with treatment monitored by GINA's grade of disease clinical control (control group)&#xD;
&#xD;
        2. Assessment of corelation of FeNO (ppb) with symptom score (points)and lung function&#xD;
           (FEV1)&#xD;
&#xD;
        3. Comparison of values of non-specific bronchial hyperresponsiveness with methacholine&#xD;
           (PC20M)between both study groups after 12. months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is one of the most common chronic disease worldwide, imposing a substantial social&#xD;
      burden on both children and adults.&#xD;
&#xD;
      What needs to be kept in mind, especially in assessing treatment effect of allergic&#xD;
      inflammation in children with asthma, is that symptom score and spirometry measures have&#xD;
      limitations, mainly their subjectivity (symptom scores), wide variability, and lack of&#xD;
      stability in short time period (symptom scores and spirometry measures).&#xD;
&#xD;
      Monitoring allergic inflammation in the course of asthma in children with exhaled nitric&#xD;
      oxide measurement (FeNO) may allow to titrate the dose of inhaled glucocorticosteroids more&#xD;
      precisely, depending on individual patients requirements.&#xD;
&#xD;
      The aim of this study is to assess the utility of FeNO in treatment monitoring in children&#xD;
      with asthma.&#xD;
&#xD;
      According to the aim of the study following assumptions are formulated:&#xD;
&#xD;
        1. Comparison of annual cumulative steroid dose, number of bronchodilator doses taken,&#xD;
           number of asthma exacerbation, number of hospitalisation due to asthma, between group of&#xD;
           children with asthma with FeNO monitored treatment (study group), and group of children&#xD;
           with treatment monitored by GINA's grade of disease clinical control (control group)&#xD;
&#xD;
        2. Assessment of corelation of FeNO (ppb) with symptom score (points)and lung function&#xD;
           (FEV1)&#xD;
&#xD;
        3. Comparison of values of non-specific bronchial hyperresponsiveness with methacholine&#xD;
           (PC20M)between both study groups after 12. months of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of the disease</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>children with asthma with FeNO monitored treatment (study group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>group of children with treatment monitored by GINA's grade of disease clinical control (control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>exhaled nitric oxide measurement</intervention_name>
    <description>exhaled nitric oxide measurement</description>
    <arm_group_label>1</arm_group_label>
    <other_name>exhaled nitric oxide measurement (Sievers FeNO analyzer)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchial hyperresponsiveness with methacholine (PC20M)</intervention_name>
    <description>bronchial hyperresponsiveness with methacholine (PC20M)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>PC20M Jaeger APS system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>symptom score diary (according to 2007 GINA guidelines)</intervention_name>
    <description>symptom score diary (according to 2007 GINA guidelines)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FeNO values above the norm for age and inadequate asthma control (based GINA&#xD;
             guidelines)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of other perennial and seasonal allergies&#xD;
&#xD;
          -  presence of other chronic diseases&#xD;
&#xD;
          -  excluded medications: systemic glucocorticosteroids 3 months before enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Sołoniewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Sołoniewicz, MD</last_name>
    <phone>00 48 42 6895972</phone>
    <email>alergol@kopernik.lodz.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sołoniewicz, MD</last_name>
      <phone>00 48 42 6895972</phone>
      <email>alergol@kopernik.lodz.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Sołoniewicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lodz</investigator_affiliation>
    <investigator_full_name>Iwona Stelmach</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>exhaled nitric oxide</keyword>
  <keyword>asthma</keyword>
  <keyword>children</keyword>
  <keyword>inhaled glucocorticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

